December 30, 2015By Mark Terry, BioSpace.com Breaking News Staff   Canton, Mass.-based Collegium Pharmaceutical, Inc. (COLL), announced yesterday that it has delayed the launch of its pain medication Xtampza because of a patent lawsuit filed by Purdue Pharma. On Nov. 9, the U.S. Food and Drug Administration gave Xtampza ER (oxycodone) extended-release capsules tentative approval […]

SAN FRANCISCO – Only months after what appeared to be a turnaround for struggling KaloBios Pharmaceuticals (KBIO), the cancer-making drug company has filed for Chapter 11 bankruptcy following the arrest of Martin Shkreli, its most recent chief executive officer and one of its largest shareholders. On Tuesday, the company filed for bankruptcy protection in U.S. […]

December 29, 2015By Alex Keown, BioSpace.com Breaking News Staff   NEW YORK – Shares of Anavex Life Sciences (AVXL) are down more than 15 percent after the company revealed in a 10-K filing it received a subpoena from the U.S. Securities and Exchange Commission regarding “unusual activity” in the market over company shares. Anavex said […]

-POZEN schedules stockholder meeting for February 2, 2016-  -Plan to re-file YOSPRALA™ New Drug Application early in the second quarter; Approval and launch targeted in fourth quarter-  CHAPEL HILL, N.C., Dec. 28, 2015 /PRNewswire/ — POZEN Inc. (“POZEN”) (NASDAQ: POZN) today announced that the registration statement on Form S-4 filed by Aralez Pharmaceuticals Inc. (“Aralez”) on […]

Valeant Pharmaceuticals International Inc said a group of company executives will take over in an interim capacity, until CEO Michael Pearson returns from medical leave. Pearson, who joined Valeant as CEO in 2010 after a 23-year career at McKinsey & Company, will be on a medical leave of absence, effective immediately, the company said in […]

Proteostasis Therapeutics, which is developing combination therapeutics that use amplifier molecules to modulate proteins, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering. The Cambridge, MA-based company, which was founded in 2006 and booked $4 million in sales for the 12 months ended September 30, 2015, plans […]

December 28, 2015By Mark Terry, BioSpace.com Breaking News Staff   Lexington, Mass.-based Agenus Inc. (AGEN) announced last week that it was acquiring PhosImmune Inc. for $9.9 million, with an additional $35 million in milestone payments. Agenus focuses on immuno-oncology. It has an AutoSynVax vaccine program that targets patient-specific tumor neoantigens. PhosImmune has numerous neoantigen assets. […]

Illinois-based Baxalta (BXLT) is still playing hard to get, as Dublin-based Shire (SHPGY) sweetened its deal to acquire the company. In July, Shire made a bid for Baxalta, which wasn’t accepted. In early August, Shire went public with the offer in hopes of pressuring the Baxalta board and shareholders to consider the deal. Baxalta had […]

Celgene Corp said it would allow for the sale of a generic version of its flagship multiple myeloma drug, Revlimid, in the United States over a year before patents covering the drug expire. The company said it would provide India-based Natco Pharma Ltd and its U.S. partner, Arrow International Limited, a unit of Allergan Plc, […]

December 22, 2015 By Mark Terry, BioSpace.com Breaking News Staff   Munich, Germany-based Medigene AG (MDGEF.PK) announced yesterday that it had sold its spinoff company, Catherex, Inc., to Amgen (AMGN). Medigene, as primary Catherex shareholder, will receive about 40 percent of the payments from Amgen. Catherex shareholders will receive an upfront payment of $10.5 million […]